{
    "hands_on_practices": [
        {
            "introduction": "The foundation of precision oncology is the accurate assessment of disease status. In early-stage oral cancer, determining if cancer has spread to nearby lymph nodes is a critical step, and the sentinel lymph node biopsy (SLNB) is a key diagnostic tool. This practice problem guides you through the statistical principles that underpin the interpretation of such tests, allowing you to calculate their predictive values and understand their real-world performance in a patient cohort .",
            "id": "4755983",
            "problem": "A precision diagnostic is being evaluated to stage occult cervical lymph node metastasis in early-stage oral cavity squamous cell carcinoma, where the decision to perform elective neck dissection and to tailor adjuvant systemic therapy relies on accurate nodal status. The test is a sentinel lymph node biopsy (SLNB) enhanced with cytokeratin immunohistochemistry (IHC). In the clinically node-negative population under consideration, the prevalence of occult nodal metastasis is $0.20$. Validation data for the SLNB protocol show a sensitivity of $0.90$ and a specificity of $0.95$. Using only foundational definitions of sensitivity, specificity, and Bayesâ€™ theorem, first compute the positive predictive value (PPV) and negative predictive value (NPV) in this setting, expressing all probabilities as decimals. Next, apply these characteristics to a cohort of $100$ consecutive, otherwise similar patients and estimate the expected numbers of true positives, false positives, true negatives, and false negatives. Finally, report the total expected number of correct classifications in the cohort as your final answer. If any intermediate quantities do not simplify to exact integers, retain exact decimal or fractional values. The final reported count of correct classifications must be an exact integer.",
            "solution": "The problem is valid as it is scientifically grounded, well-posed, and all necessary information is provided.\n\nLet $D+$ be the event that a patient has occult nodal metastasis (disease is present), and $D-$ be the event that the patient does not have the disease. Let $T+$ be the event of a positive test result, and $T-$ be the event of a negative test result.\n\nThe given information can be stated in terms of conditional probabilities:\nThe prevalence of the disease is the prior probability of a patient having the disease:\n$$P(D+) = 0.20$$\nThe sensitivity of the test is the probability of a positive test given the disease is present:\n$$P(T+|D+) = 0.90$$\nThe specificity of the test is the probability of a negative test given the disease is absent:\n$$P(T-|D-) = 0.95$$\n\nFrom this information, we derive the complementary probabilities:\nThe probability of a patient not having the disease:\n$$P(D-) = 1 - P(D+) = 1 - 0.20 = 0.80$$\nThe false negative rate (the probability of a negative test given the disease is present):\n$$P(T-|D+) = 1 - P(T+|D+) = 1 - 0.90 = 0.10$$\nThe false positive rate (the probability of a positive test given the disease is absent):\n$$P(T+|D-) = 1 - P(T-|D-) = 1 - 0.95 = 0.05$$\n\nThe first task is to compute the positive predictive value (PPV) and the negative predictive value (NPV).\n\nThe PPV is the probability that a patient with a positive test result actually has the disease, denoted $P(D+|T+)$. We use Bayes' theorem:\n$$PPV = P(D+|T+) = \\frac{P(T+|D+) P(D+)}{P(T+)}$$\nTo calculate this, we first need the total probability of a positive test, $P(T+)$, which is found using the law of total probability:\n$$P(T+) = P(T+|D+)P(D+) + P(T+|D-)P(D-)$$\nSubstituting the known values:\n$$P(T+) = (0.90)(0.20) + (0.05)(0.80) = 0.18 + 0.04 = 0.22$$\nNow, we can compute the PPV:\n$$PPV = \\frac{0.18}{0.22} = \\frac{18}{22} = \\frac{9}{11} \\approx 0.8182$$\nSo, the positive predictive value is exactly $\\frac{9}{11}$, or approximately $0.8182$.\n\nThe NPV is the probability that a patient with a negative test result is actually disease-free, denoted $P(D-|T-)$. Using Bayes' theorem again:\n$$NPV = P(D-|T-) = \\frac{P(T-|D-) P(D-)}{P(T-)}$$\nFirst, we find the total probability of a negative test, $P(T-)$:\n$$P(T-) = P(T-|D+)P(D+) + P(T-|D-)P(D-)$$\nSubstituting the known values:\n$$P(T-) = (0.10)(0.20) + (0.95)(0.80) = 0.02 + 0.76 = 0.78$$\nAs a consistency check, $P(T+) + P(T-) = 0.22 + 0.78 = 1.00$.\nNow, we can compute the NPV:\n$$NPV = \\frac{0.76}{0.78} = \\frac{76}{78} = \\frac{38}{39} \\approx 0.9744$$\nSo, the negative predictive value is exactly $\\frac{38}{39}$, or approximately $0.9744$.\n\nThe second task is to apply these findings to a cohort of $N=100$ patients to find the expected number of true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN).\n\nThe expected number of patients with the disease in the cohort is:\n$$N_{D+} = N \\times P(D+) = 100 \\times 0.20 = 20$$\nThe expected number of patients without the disease is:\n$$N_{D-} = N \\times P(D-) = 100 \\times 0.80 = 80$$\n\nWe can now calculate the expected counts for each category:\n-   Expected True Positives ($E[TP]$): Patients with the disease who test positive.\n$$E[TP] = N_{D+} \\times P(T+|D+) = 20 \\times 0.90 = 18$$\n-   Expected False Negatives ($E[FN]$): Patients with the disease who test negative.\n$$E[FN] = N_{D+} \\times P(T-|D+) = 20 \\times 0.10 = 2$$\n-   Expected True Negatives ($E[TN]$): Patients without the disease who test negative.\n$$E[TN] = N_{D-} \\times P(T-|D-) = 80 \\times 0.95 = 76$$\n-   Expected False Positives ($E[FP]$): Patients without the disease who test positive.\n$$E[FP] = N_{D-} \\times P(T+|D-) = 80 \\times 0.05 = 4$$\n\nThe final task is to report the total expected number of correct classifications. Correct classifications are the sum of true positives and true negatives.\n$$E[\\text{Correct Classifications}] = E[TP] + E[TN]$$\nSubstituting the calculated values:\n$$E[\\text{Correct Classifications}] = 18 + 76 = 94$$\nThe total expected number of correct classifications in the cohort of $100$ patients is $94$. This is an exact integer as required by the problem statement.",
            "answer": "$$\n\\boxed{94}\n$$"
        },
        {
            "introduction": "Selecting the right patient for the right therapy is the essence of precision treatment. For immunotherapies like pembrolizumab, the decision often hinges on biomarkers such as Programmed death-ligand 1 (PD-L1) expression, which is quantified using the Combined Positive Score (CPS). This exercise gives you practical experience in calculating the CPS from pathological data and applying it to determine patient eligibility for treatment, demonstrating a direct link between a molecular diagnostic and a clinical action plan .",
            "id": "4755951",
            "problem": "An oral cavity squamous cell carcinoma, a subtype of Head and Neck Squamous Cell Carcinoma (HNSCC), is profiled for Programmed death-ligand 1 (PD-L1) expression by immunohistochemistry. Precision immunotherapy selection for the anti-Programmed cell death protein 1 (PD-1) antibody pembrolizumab in this setting is commonly guided by the Combined Positive Score (CPS), which by definition is the ratio of the number of PD-L1 staining cells (including tumor cells, lymphocytes, and macrophages) to the total number of viable tumor cells, scaled by a factor of $100$ to yield a unitless index. In a representative field curated to avoid necrotic areas and overlapping nuclei, there are $150$ PD-L1 staining cells and $1000$ viable tumor cells. Starting from the stated definitional ratio for CPS, derive the appropriate expression, compute the CPS, and determine whether the tumor meets an eligibility threshold of $\\mathrm{CPS} \\geq 10$ for pembrolizumab use in this disease context. Express your final answer as the numerical value of the Combined Positive Score (no units, no percentage sign). Do not round unless necessary.",
            "solution": "The problem is validated as scientifically grounded, well-posed, objective, and complete. All necessary information is provided to perform the required calculation and assessment. The context is a standard application of a biomarker in clinical oncology, and the provided definition and values are consistent with established practice.\n\nThe problem asks for the derivation and computation of the Combined Positive Score (CPS) and an assessment of eligibility for immunotherapy based on a given threshold.\n\nFirst, we formalize the definition of the CPS. Let $N_{\\text{PD-L1+}}$ represent the number of PD-L1 staining cells, which includes tumor cells, lymphocytes, and macrophages. Let $N_{\\text{tumor}}$ represent the total number of viable tumor cells. According to the problem statement, the CPS is defined as the ratio of these two quantities, scaled by a factor of $100$. The definitional equation is:\n$$ \\text{CPS} = \\frac{N_{\\text{PD-L1+}}}{N_{\\text{tumor}}} \\times 100 $$\nThis formula yields a unitless index, as specified.\n\nThe problem provides the following data from a representative field:\nThe number of PD-L1 staining cells, $N_{\\text{PD-L1+}} = 150$.\nThe total number of viable tumor cells, $N_{\\text{tumor}} = 1000$.\n\nWe substitute these values into the definitional equation for the CPS:\n$$ \\text{CPS} = \\frac{150}{1000} \\times 100 $$\n\nPerforming the division first:\n$$ \\frac{150}{1000} = 0.15 $$\n\nNow, multiplying by the scaling factor of $100$:\n$$ \\text{CPS} = 0.15 \\times 100 = 15 $$\nThe calculated Combined Positive Score is $15$.\n\nThe second part of the task is to determine if the tumor meets the eligibility threshold for pembrolizumab treatment in this context. The specified threshold is $\\text{CPS} \\geq 10$.\n\nWe compare our calculated CPS value to this threshold:\n$$ 15 \\geq 10 $$\nThis inequality is true. Therefore, the tumor meets the eligibility criterion for the administration of pembrolizumab.\n\nThe question asks for the numerical value of the Combined Positive Score as the final answer. The calculated value is $15$.",
            "answer": "$$\n\\boxed{15}\n$$"
        },
        {
            "introduction": "Advancing the field of precision oncology requires rigorous clinical trials to validate new targeted therapies. A fundamental question in trial design is, \"How many patients do we need to enroll to obtain a conclusive result?\" This advanced practice problem walks you through the statistical derivation and calculation of sample size, providing insight into the essential planning required to test the efficacy of a new treatment within a molecularly defined patient group .",
            "id": "4755851",
            "problem": "A clinical trial in Oral Squamous Cell Carcinoma (OSCC) is designed within a precision oncology framework to compare the overall response rate to therapy between two molecularly defined cohorts: patients with Fibroblast Growth Factor Receptor (FGFR) gene alterations receiving FGFR-targeted therapy, and patients without FGFR alterations receiving standard immunotherapy. Suppose the response probabilities are hypothesized to be $p_{1} = 0.45$ in the FGFR-altered cohort and $p_{2} = 0.25$ in the non-altered cohort, giving a planned response rate difference $\\Delta = p_{1} - p_{2} = 0.20$. Assume independent Bernoulli outcomes, equal allocation with $n$ patients per group, and a two-sided two-sample proportion $z$-test at significance level $\\alpha = 0.05$ and power $0.8$.\n\nStarting from first principles of the Central Limit Theorem for binomial proportions, the definitions of Type I error ($\\alpha$) and power ($1 - \\beta$), and the standard construction of a two-sided critical region for a difference in proportions under the null hypothesis using the pooled variance, derive the per-group sample size $n$ required to detect the specified difference $\\Delta$ with the given $\\alpha$ and power. Use the two-sided test with pooled standard error under the null hypothesis and the unpooled standard error under the alternative hypothesis. Take $z_{1-\\alpha/2}$ and $z_{1-\\beta}$ to be the standard normal quantiles corresponding to the two-sided test size and target power, respectively.\n\nCompute the numerical value of $n$ under the above assumptions. Round any intermediate numerical computations to four significant figures. After obtaining the non-integer $n$, apply the ceiling function to report the minimal integer per-group sample size. The final answer must be a single number with no units.",
            "solution": "The problem asks for the derivation of the per-group sample size $n$ for a two-sample proportion test, followed by a numerical calculation.\n\n### Problem Validation\n**Step 1: Extract Givens**\n-   Response probability in cohort 1 (FGFR-altered): $p_{1} = 0.45$\n-   Response probability in cohort 2 (non-altered): $p_{2} = 0.25$\n-   Planned response rate difference: $\\Delta = p_{1} - p_{2} = 0.20$\n-   Allocation: equal, with $n$ patients per group, so $n_1=n_2=n$.\n-   Outcomes: Independent Bernoulli trials.\n-   Test type: Two-sided two-sample proportion $z$-test.\n-   Significance level: $\\alpha = 0.05$.\n-   Power: $1 - \\beta = 0.8$.\n-   Standard error calculation: Pooled standard error under the null hypothesis ($H_0$), unpooled standard error under the alternative hypothesis ($H_a$).\n-   Quantiles: $z_{1-\\alpha/2}$ and $z_{1-\\beta}$.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is well-defined and scientifically sound.\n-   **Scientifically Grounded:** It presents a standard sample size calculation problem, a fundamental task in designing clinical trials. The context of precision oncology in Oral Squamous Cell Carcinoma is realistic, and the specified statistical parameters ($\\alpha$, power, effect size) are conventional.\n-   **Well-Posed:** All necessary information is provided to derive a unique numerical answer for the sample size $n$. The methodology is explicitly stated, removing ambiguity.\n-   **Objective:** The problem is framed using precise, quantitative language and is free of subjective elements.\n-   **Consistency:** The provided data is internally consistent and complete for the task.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A full derivation and solution will be provided.\n\n### Derivation of the Sample Size Formula\n\nLet $X_1$ and $X_2$ be the number of responders in the FGFR-altered and non-altered cohorts, respectively. The outcomes are modeled as independent binomial random variables: $X_1 \\sim \\text{Binomial}(n, p_1)$ and $X_2 \\sim \\text{Binomial}(n, p_2)$. The corresponding sample proportions are $\\hat{p}_1 = X_1/n$ and $\\hat{p}_2 = X_2/n$.\n\nBy the Central Limit Theorem (CLT), for a sufficiently large $n$, the sample proportions are approximately normally distributed:\n$$ \\hat{p}_1 \\approx N\\left(p_1, \\frac{p_1(1-p_1)}{n}\\right) $$\n$$ \\hat{p}_2 \\approx N\\left(p_2, \\frac{p_2(1-p_2)}{n}\\right) $$\nSince the two samples are independent, the difference in sample proportions, $\\hat{p}_1 - \\hat{p}_2$, is also approximately normally distributed with mean $E[\\hat{p}_1 - \\hat{p}_2] = p_1 - p_2$ and variance $Var(\\hat{p}_1 - \\hat{p}_2) = \\frac{p_1(1-p_1)}{n} + \\frac{p_2(1-p_2)}{n}$.\n\nThe hypotheses for the two-sided test are:\n-   Null Hypothesis ($H_0$): $p_1 = p_2$. This implies the difference in proportions is zero, $p_1 - p_2 = 0$.\n-   Alternative Hypothesis ($H_a$): $p_1 \\neq p_2$.\n\n**Distribution under the Null Hypothesis ($H_0$)**\nUnder $H_0$, let the common unknown proportion be $p$. The distribution of the difference is:\n$$ (\\hat{p}_1 - \\hat{p}_2) \\big| H_0 \\approx N\\left(0, \\frac{p(1-p)}{n} + \\frac{p(1-p)}{n}\\right) = N\\left(0, \\frac{2p(1-p)}{n}\\right) $$\nFor sample size planning, the unknown common proportion $p$ is estimated using the average of the hypothesized proportions under the alternative, $\\bar{p} = \\frac{p_1+p_2}{2}$. This is consistent with using a pooled variance for the test statistic. The standard error under $H_0$ is thus:\n$$ SE_0 = \\sqrt{\\frac{2\\bar{p}(1-\\bar{p})}{n}} $$\nThe two-sided test rejects $H_0$ at a significance level $\\alpha$ if the observed difference $|\\hat{p}_1 - \\hat{p}_2|$ is greater than a critical value $C$. This critical value is defined by:\n$$ C = z_{1-\\alpha/2} \\cdot SE_0 = z_{1-\\alpha/2} \\sqrt{\\frac{2\\bar{p}(1-\\bar{p})}{n}} $$\n\n**Distribution under the Alternative Hypothesis ($H_a$)**\nUnder the specific alternative we wish to detect, $p_1$ and $p_2$ are given. The distribution of the difference is:\n$$ (\\hat{p}_1 - \\hat{p}_2) \\big| H_a \\approx N\\left(p_1 - p_2, \\frac{p_1(1-p_1)}{n} + \\frac{p_2(1-p_2)}{n}\\right) $$\nThe problem specifies using the unpooled standard error under the alternative. Let $\\Delta = p_1 - p_2$. The standard error under $H_a$ is:\n$$ SE_A = \\sqrt{\\frac{p_1(1-p_1) + p_2(1-p_2)}{n}} $$\nPower ($1-\\beta$) is the probability of correctly rejecting $H_0$ when $H_a$ is true. Assuming $\\Delta > 0$, this is primarily the probability that $\\hat{p}_1 - \\hat{p}_2 > C$:\n$$ 1-\\beta = P(\\hat{p}_1 - \\hat{p}_2 > C | H_a) $$\nTo evaluate this probability, we standardize the expression with respect to the distribution under $H_a$:\n$$ 1-\\beta = P\\left( \\frac{(\\hat{p}_1 - \\hat{p}_2) - \\Delta}{SE_A} > \\frac{C - \\Delta}{SE_A} \\right) $$\nThe term on the left inside the probability is a standard normal variable $Z$. Thus, the term on the right must be the $\\beta$ quantile of the standard normal distribution, which is $z_\\beta = -z_{1-\\beta}$.\n$$ \\frac{C - \\Delta}{SE_A} = -z_{1-\\beta} \\implies C = \\Delta - z_{1-\\beta} SE_A $$\n$$ C = (p_1 - p_2) - z_{1-\\beta} \\sqrt{\\frac{p_1(1-p_1) + p_2(1-p_2)}{n}} $$\n\n**Solving for Sample Size $n$**\nWe now have two expressions for the critical value $C$. By equating them, we can solve for $n$:\n$$ z_{1-\\alpha/2} \\sqrt{\\frac{2\\bar{p}(1-\\bar{p})}{n}} = (p_1 - p_2) - z_{1-\\beta} \\sqrt{\\frac{p_1(1-p_1) + p_2(1-p_2)}{n}} $$\nRearranging to group terms with $1/\\sqrt{n}$:\n$$ (p_1 - p_2) = z_{1-\\alpha/2} \\frac{\\sqrt{2\\bar{p}(1-\\bar{p})}}{\\sqrt{n}} + z_{1-\\beta} \\frac{\\sqrt{p_1(1-p_1) + p_2(1-p_2)}}{\\sqrt{n}} $$\n$$ \\sqrt{n} (p_1-p_2) = z_{1-\\alpha/2} \\sqrt{2\\bar{p}(1-\\bar{p})} + z_{1-\\beta} \\sqrt{p_1(1-p_1) + p_2(1-p_2)} $$\nIsolating $\\sqrt{n}$ and squaring both sides yields the formula for the per-group sample size $n$:\n$$ n = \\left( \\frac{z_{1-\\alpha/2} \\sqrt{2\\bar{p}(1-\\bar{p})} + z_{1-\\beta} \\sqrt{p_1(1-p_1) + p_2(1-p_2)}}{p_1 - p_2} \\right)^2 $$\n\n### Numerical Calculation\n\nThe given values are:\n-   $p_1 = 0.45$, $p_2 = 0.25$, so $\\Delta = p_1 - p_2 = 0.20$.\n-   $\\alpha = 0.05 \\implies z_{1-\\alpha/2} = z_{0.975} = 1.9600$.\n-   $1-\\beta = 0.8 \\implies \\beta = 0.2 \\implies z_{1-\\beta} = z_{0.8} = 0.8416$.\n\nFirst, we compute the necessary components, rounding intermediate calculations to four significant figures as instructed.\n1.  Average proportion: $\\bar{p} = \\frac{0.45+0.25}{2} = 0.35$.\n2.  Variance components under $H_a$:\n    -   $p_1(1-p_1) = 0.45(0.55) = 0.2475$.\n    -   $p_2(1-p_2) = 0.25(0.75) = 0.1875$.\n    -   Sum of variances: $p_1(1-p_1) + p_2(1-p_2) = 0.2475 + 0.1875 = 0.4350$.\n3.  Pooled variance component under $H_0$:\n    -   $2\\bar{p}(1-\\bar{p}) = 2(0.35)(1-0.35) = 2(0.35)(0.65) = 0.4550$.\n\nNow, we compute the terms in the numerator of the formula for $\\sqrt{n}$:\n1.  Square roots of variance terms:\n    -   $\\sqrt{2\\bar{p}(1-\\bar{p})} = \\sqrt{0.4550} \\approx 0.6745$.\n    -   $\\sqrt{p_1(1-p_1) + p_2(1-p_2)} = \\sqrt{0.4350} \\approx 0.6595$.\n2.  Numerator terms:\n    -   $z_{1-\\alpha/2} \\sqrt{2\\bar{p}(1-\\bar{p})} \\approx 1.9600 \\times 0.6745 = 1.32202 \\approx 1.322$.\n    -   $z_{1-\\beta} \\sqrt{p_1(1-p_1) + p_2(1-p_2)} \\approx 0.8416 \\times 0.6595 = 0.5550272 \\approx 0.5550$.\n3.  Sum of numerator terms:\n    -   $1.322 + 0.5550 = 1.877$.\n\nNow, we compute $\\sqrt{n}$:\n$$ \\sqrt{n} = \\frac{1.877}{0.20} = 9.385 $$\n\nFinally, we compute $n$:\n$$ n = (9.385)^2 = 88.078225 \\approx 88.08 $$\nSince the number of patients must be an integer, we apply the ceiling function to ensure the required power is met or exceeded.\n$$ n_{required} = \\lceil 88.08 \\rceil = 89 $$\nThus, a sample size of $89$ patients per group is required.",
            "answer": "$$\n\\boxed{89}\n$$"
        }
    ]
}